Kenya
![July 2022: Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya](https://icap.columbia.edu/wp-content/uploads/Untitled-design-16-1080x675.png)
July 2022: Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya
Article and Study Summary: Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial Published in: Lancet HIV. 2022;9(7):e464-e473 https://doi.org/10.1016/S2352-3018(22)00126-6 Authors: Ngure...Characteristics Of Users of HIV Self-Testing in Kenya, Outcomes, And Factors Associated with Use: Results from A Population-Based HIV Impact Assessment, 2018
Authors: Jonathan Mwangi, Fredrick Miruka, Mary Mugambi, Ahmed Fidhow, Betty Chepkwony, Frankline Kitheka, Evelyn Ngugi, Appolonia Aoko, Catherine Ngugi, and Anthony Waruru. Abstract Background and setting About 20% of persons living with HIV aged 15–64 years did not...![Quality Improvement Capacity for Impact Project (QICIP) Report](https://icap.columbia.edu/wp-content/uploads/Untitled-design-10-1080x675.png)
Quality Improvement Capacity for Impact Project (QICIP) Report
The Quality Improvement Capacity for Impact Project (QICIP), funded by PEPFAR through the U.S. Health Resources and Services Administration (HRSA), supported projects in 11 countries that enhanced local capacity to design, implement, evaluate, document, and sustain a...![July/August 2021: Comparing Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir for second-line HIV treatment: Results of the NADIA Trial in Uganda, Kenya, and Zimbabwe](https://icap.columbia.edu/wp-content/uploads/Journal-club-1080x675.jpg)